Novo Nordisk A/S
Analysts predicted new obesity medicines would be blockbusters. Now they’re raising their forecasts
As new weight loss medications garnered buzz last year, analysts’ forecasts signaled these drugs would be blockbusters, with some of the highest estimates calling for peak sales of at least $100 billion. In recent days, the expectations are moving higher still. The initial projections were made before Wall Street saw the results of Novo Nordisk’s […]
Read More
Wager in opposition to America’s enjoy for junk food stuff? Morgan Stanley sees hard periods forward for snack stocks like Hostess
J.M. Smucker ‘s prepare to obtain Twinkies -maker Hostess Models is a risky shift, if Morgan Stanley’s most current investigate is appropriate. The company revisited its August call that a new course of body weight loss medicines would hamper expansion at some foodstuff and beverage firms . This time it backed up its thesis with […]
Read More
Ozempic, Wegovy may curb drinking, smoking and other addictive behaviors – here’s what we know
An Ozempic (semaglutide) injection pen is seen on a kitchen table in Riga, Latvia on 06 August, 2023. Jaap Arriens | Nurphoto | Getty Images Heather Le Biller shed 9 pounds within the first week of taking Novo Nordisk‘s blockbuster diabetes drug Ozempic – and then even more as she continued treatment. Le Biller, a […]
Read More
Big pharma’s blockbuster obesity drug battle is just getting started, and it’s headed for $100 billion
Ozempic drug to treat diabetes. Courtesy: Ozempic In their most recent earnings reports, Novo Nordisk and Eli Lilly proved why they are the undisputed heavyweights in the prizefight for control of the rapidly growing weight-loss medications market. Beyond staggering sales figures for Novo’s Ozempic and Wegovy and Lilly’s Mounjaro, news of a study showing Wegovy […]
Read More
Obesity drugs’ popularity put a dent in these stocks. Why analysts say they’re still worth buying
Industry analysts are insisting that new weight loss and diabetes drugs like Ozempic won’t hurt the demand for insulin pumps and continuous glucose monitors, but most investors aren’t buying it. Medical device stocks have been falling session after session, prompting UBS analyst Danielle Antalffy on Wednesday to lower her price targets for Dexcom and a […]
Read More
Blockbuster weight loss drugs Wegovy and Ozempic are being tested to treat addiction and dementia
Weight loss drugs are being assessed for their ability to treat conditions like dementia and addiction after a landmark study showed that Wegovy helped reduce the risk of heart attacks and strokes. Bloomberg | Bloomberg | Getty Images LONDON — Scientists have begun investigating whether so-called miracle obesity drugs could be used to treat conditions […]
Read More
Novo Nordisk’s Wegovy weight loss drug launches in the Uk
Offers of the weight-loss drug Wegovy from the pharmaceutical business Novo Nordisk lie on the income counter in a Danish pharmacy. Stefan Trumpf | Photo Alliance | Getty Photographs Novo Nordisk introduced its Wegovy pounds decline injection in the U.K. on Monday, advancing the drug’s rollout in Europe regardless of ongoing source constraints. The Danish […]
Read More
‘Robot pills’ could one day help patients avoid needles. The stocks are cheap, but risky
Ask most patients if they prefer to receive medicine by swallowing a pill, by injection or infusion, and most will likely opt for the pill. But that’s not always possible for drugs that use delicate molecules that can’t tolerate the physical and chemical conditions in the gastrointestinal tract. That’s where a number of early-stage drug […]
Read More
Weight loss drugmaker Novo Nordisk vies to come to be Europe’s most valuable enterprise, toppling LVMH
Denmark’s Novo Nordisk on Friday briefly overtook French luxurious merchandise behemoth LVMH to turn into Europe’s most precious corporation as traders wager on the opportunity of its pounds decline drugs. Novo Nordisk’s sector capitalization was $421 billion like unlisted stock at 9:43 a.m. London time, according to Refinitiv information cited by Reuters, vs . LVMH’s […]
Read More
Ozempic could be the next target of Medicare drug price negotiations – here’s why
A pharmacist displays boxes of Ozempic, a semaglutide injection drug used for treating type 2 diabetes made by Novo Nordisk, at Rock Canyon Pharmacy in Provo, Utah, U.S. March 29, 2023. George Frey | Reuters Ozempic, the blockbuster diabetes treatment from Novo Nordisk, could be next in line for price negotiations between manufacturers and Medicare. […]
Read More